Forte Biosciences, Inc. (FBRX) is a clinical-stage biopharmaceutical company dedicated to advancing transformative solutions in dermatology. Based in Torrance, California, it primarily focuses on developing and commercializing novel treatments for inflammatory skin diseases, leading the way in cutting-edge science and innovation within the dermatological sphere.
At the forefront of Forte Biosciences’s clinical programs is FB-401, a topically applied live biotherapeutic for the treatment of inflammatory skin diseases, including pediatric atopic dermatitis, commonly known as eczema. FB-401 has shown promising results in Phase1/2a clinical trials, reducing eczema severity with a favorable safety profile.
Forte Biosciences utilizes advanced theories in the evolving field of the human microbiome – the collective genetic material of microorganisms living in and on our bodies. The company has been matching novel research around the microbiome's importance in human health to create targeted treatments for inflammatory dermatologic conditions.
FBRX was incorporated in 2017, marking its entry into the American biotech industry with a foundation deeply rooted in the spirit of scientific innovation and patient care. Forte’s mission is encapsulated by its focus on creating unique, sophisticated treatments for diseases that often have a profoundly negative impact on quality of life, and where limited treatment options currently exist. With its efforts centered on addressing unmet needs, the company is driving progress in the dermatological field.
Forte Biosciences has assembled a team of seasoned biopharmaceutical executives and technical specialists while developing robust partnerships with leading academic institutions. It’s this combination of industry expertise, pioneering spirit, and emphasis on collaborations that fuels their success in an extremely competitive and demanding marketplace.
In February 2021, however, the company was acquired by Cytocom, Inc., a leading clinical-stage biopharmaceutical company that uses innovative platforms to enhance the body’s immune response, primarily in the development of novel treatments for diseases within immune and inflammatory pathways. As a result of this acquisition, Forte Biosciences, Inc. is now operating as a wholly-owned subsidiary of Cytocom, but remains committed to their original goal of developing innovative remedies for inflammatory skin diseases. The firm's promising developments in dermatology continue to give hope to patients worldwide, showing significant potential to change the way these conditions are treated.